CytomX Therapeutics reported encouraging clinical results for Varseta-M, a treatment targeting late-line colorectal cancer, showing 20–32% response rates and 7 months progression-free survival. The drug has received FDA Fast Track designation and is set for pivotal trials starting in early 2027. The company also benefits from strategic partnerships with Amgen, Regeneron, and Moderna, which validate its PROBODY platform and offer potential milestone payments up to $6.7 billion. Despite revenue pressure from ending legacy partnerships and high dilution, the stock is valued at $3.50 per share versus the current $2.30, indicating significant upside if trials succeed.
CytomX's clinical progress with Varseta-M provides context for health sector activity. For readers following health stocks, 85 of 150 traded on Pluang rose today while 56 fell. Notable movers include ACHC at USD 34.05 (+5.58%), RVMD at USD 210.09 (+5.20%), and LFST at USD 14.88 (+4.71%). This data is as of Nov 05, 2026 18:11 WIB.
Perimeter Group Inc. announced a net income of $304.5 million for Q3 2026, reversing a prior year loss of $90.7 million, with net sales up 24% to $389.9 million. Growth was driven by a 14% increase in Fire Safety sales and an 84% surge in Specialty P...
ACM Research reported a 37% year-over-year revenue increase to $367.7 million in Q3 2026, driven by strong demand in electrochemical plating (ECP) and advanced packaging technologies. The company is expanding manufacturing capacity and global sales e...
Purple has renewed its partnership with Lucid Motors to continue providing WiFi services across Lucid's operations in Riyadh. This renewal ensures that both staff and visitors have secure and easy internet access, supporting Lucid's growing presence ...
Investec Bank Plc, acting as joint broker to SThree Plc, disclosed public dealings involving the purchase and sale of 118,333 ordinary shares each on November 4, 2026. The transactions were conducted within a price range of 295 to 304 per share. Ther...
Investec Bank plc, acting as joint broker for Gamma Communications Plc, disclosed transactions involving nearly one million ordinary shares on November 4, 2026. The bank purchased 999,970 shares at 1098 pence each and sold 962,128 shares at prices be...
